In-vitro study of lithium binding by sodium zirconium cyclosilicate (Lokelma®) or patiromer (Veltassa®)
AbstractLithium poisoning remains common. Symptomatic lithium poisonings often require hemodialysis, especially when the patient has impaired renal function. An effective and non-invasive treatment to remove excess lithium would be desirable. We tested two recently approved, orally administered pota...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-11-01
|
| Series: | Toxicology Communications |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/24734306.2021.2007602 |
| _version_ | 1797300166809616384 |
|---|---|
| author | David B. Liss Stephen M. Roper Dennis J. Dietzen Michael E. Mullins |
| author_facet | David B. Liss Stephen M. Roper Dennis J. Dietzen Michael E. Mullins |
| author_sort | David B. Liss |
| collection | DOAJ |
| description | AbstractLithium poisoning remains common. Symptomatic lithium poisonings often require hemodialysis, especially when the patient has impaired renal function. An effective and non-invasive treatment to remove excess lithium would be desirable. We tested two recently approved, orally administered potassium binders in an in-vitro model. We used lithium-heparin tubes as both the source of lithium based prior studies showing the different volumes of serum in lithium-heparin tubes will produce apparent lithium concentrations in the range of toxicity (2.5 mmol/L and 5 mmol/L). We added three different volumes (0.5 mL, 0.75 mL, or 1.0 mL) of normal saline (NS) to the tubes. We calculated concentrations of sodium zirconium cyclosilicate (SZC, Lokelma®) and patiromer (Veltassa®) to simulate the ratio of drug to total body water for a 70 kg human. We prepared stock suspensions with different concentrations above and below the estimated ratios. We added varying concentrations of SZC or patiromer to tubes containing of NS. We measured sodium and lithium concentrations in duplicate for each concentration. Neither SZC nor patiromer reduced the lithium concentration across the range of concentrations in this in-vitro study. |
| first_indexed | 2024-03-07T23:03:21Z |
| format | Article |
| id | doaj.art-a04bb8c9e90649379b852d4c24e5b32b |
| institution | Directory Open Access Journal |
| issn | 2473-4306 |
| language | English |
| last_indexed | 2024-03-07T23:03:21Z |
| publishDate | 2021-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Toxicology Communications |
| spelling | doaj.art-a04bb8c9e90649379b852d4c24e5b32b2024-02-22T09:16:09ZengTaylor & Francis GroupToxicology Communications2473-43062021-11-015116116410.1080/24734306.2021.2007602In-vitro study of lithium binding by sodium zirconium cyclosilicate (Lokelma®) or patiromer (Veltassa®)David B. Liss0Stephen M. Roper1Dennis J. Dietzen2Michael E. Mullins3Department of Emergency Medicine, Washington University School of Medicine, Saint Louis, MO, USADepartment of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USADepartment of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USADepartment of Emergency Medicine, Washington University School of Medicine, Saint Louis, MO, USAAbstractLithium poisoning remains common. Symptomatic lithium poisonings often require hemodialysis, especially when the patient has impaired renal function. An effective and non-invasive treatment to remove excess lithium would be desirable. We tested two recently approved, orally administered potassium binders in an in-vitro model. We used lithium-heparin tubes as both the source of lithium based prior studies showing the different volumes of serum in lithium-heparin tubes will produce apparent lithium concentrations in the range of toxicity (2.5 mmol/L and 5 mmol/L). We added three different volumes (0.5 mL, 0.75 mL, or 1.0 mL) of normal saline (NS) to the tubes. We calculated concentrations of sodium zirconium cyclosilicate (SZC, Lokelma®) and patiromer (Veltassa®) to simulate the ratio of drug to total body water for a 70 kg human. We prepared stock suspensions with different concentrations above and below the estimated ratios. We added varying concentrations of SZC or patiromer to tubes containing of NS. We measured sodium and lithium concentrations in duplicate for each concentration. Neither SZC nor patiromer reduced the lithium concentration across the range of concentrations in this in-vitro study.https://www.tandfonline.com/doi/10.1080/24734306.2021.2007602Lithiumsodium zirconium cyclosilicatepatiromerion exchange resinin-vitro |
| spellingShingle | David B. Liss Stephen M. Roper Dennis J. Dietzen Michael E. Mullins In-vitro study of lithium binding by sodium zirconium cyclosilicate (Lokelma®) or patiromer (Veltassa®) Toxicology Communications Lithium sodium zirconium cyclosilicate patiromer ion exchange resin in-vitro |
| title | In-vitro study of lithium binding by sodium zirconium cyclosilicate (Lokelma®) or patiromer (Veltassa®) |
| title_full | In-vitro study of lithium binding by sodium zirconium cyclosilicate (Lokelma®) or patiromer (Veltassa®) |
| title_fullStr | In-vitro study of lithium binding by sodium zirconium cyclosilicate (Lokelma®) or patiromer (Veltassa®) |
| title_full_unstemmed | In-vitro study of lithium binding by sodium zirconium cyclosilicate (Lokelma®) or patiromer (Veltassa®) |
| title_short | In-vitro study of lithium binding by sodium zirconium cyclosilicate (Lokelma®) or patiromer (Veltassa®) |
| title_sort | in vitro study of lithium binding by sodium zirconium cyclosilicate lokelma r or patiromer veltassa r |
| topic | Lithium sodium zirconium cyclosilicate patiromer ion exchange resin in-vitro |
| url | https://www.tandfonline.com/doi/10.1080/24734306.2021.2007602 |
| work_keys_str_mv | AT davidbliss invitrostudyoflithiumbindingbysodiumzirconiumcyclosilicatelokelmaorpatiromerveltassa AT stephenmroper invitrostudyoflithiumbindingbysodiumzirconiumcyclosilicatelokelmaorpatiromerveltassa AT dennisjdietzen invitrostudyoflithiumbindingbysodiumzirconiumcyclosilicatelokelmaorpatiromerveltassa AT michaelemullins invitrostudyoflithiumbindingbysodiumzirconiumcyclosilicatelokelmaorpatiromerveltassa |